HHS has moved to discontinue U.S. COVID-19 Emergency Use Authorization declarations for medical devices, with termination scheduled in 180 days for the device-specific determinations. HHS also indicated drug and biologics EUAs will end later—12 months from now—signaling a shift away from emergency authorities. The agency said the change is intended to reinforce public confidence that emergency powers are temporary, while providing manufacturers and health systems time to transition to standard FDA review pathways. HHS cited earlier analyses that tracked the scale of EUA approvals and production during the pandemic.